ReviewInternational journal of ophthalmology2022
Progress of clinical therapies for dry age-related macular degeneration.
Review in International journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Association of Antibiotic Use and New-Onset ICD Coding of Geographic Atrophy.Investigative ophthalmology & visual science · 2026Article
- Anatomical and functional results of patients with late-stage age-related macular degeneration 6 months after smaller-incision new-generation implantable miniature telescope (SING IMT™) implantation.Eye (London, England) · 2025Article
- Computer modeling of bevacizumab drug distribution after intravitreal injection in rabbit and human eyes.Journal of pharmaceutical sciences · 2025Article
- Light as a Mediator of Acute and Chronic Retina Degeneration.Advances in experimental medicine and biology · 2025Review
- Photobiomodulation in Ophthalmology: A Comprehensive Review of Bench-to-Bedside Research and Clinical Integration.Cureus · 2024Review
- Article
- Article
- Investigating the causal link between gut microbiota and dry age-related macular degeneration: a bidirectional Mendelian randomization study.International journal of ophthalmology · 2024Article
- Review: Mechanisms of TIMP-3 accumulation and pathogenesis in Sorsby fundus dystrophy.Molecular vision · 2024Review
- Impact of umbelliprenin-containing niosome nanoparticles onInternational journal of ophthalmology · 2024Article
- Anti-VEGF Drugs in Age-Related Macular Degeneration: A Focus on Dosing Regimen-Related Safety and Efficacy.Drugs & aging · 2023Review
- Advanced Therapy Medicinal Products for Age-Related Macular Degeneration; Scaffold Fabrication and Delivery Methods.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Review
- Qihuang Granule protects the retinal pigment epithelium from oxidative stress via regulation of the alternative complement pathway.BMC complementary medicine and therapies · 2023Article
- Three-Month Safety and Efficacy Outcomes for the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT™).Journal of clinical medicine · 2023Article
- Identification of retinal thickness and blood flow in age-related macular degeneration with reticular pseudodrusen.International journal of ophthalmology · 2023Article
- Effect of palmitoylethanolamide on degeneration of a human-derived retinal pigment epithelial cell induced by all-trans retinal.International journal of ophthalmology · 2023Article
- Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment.Cureus · 2022Review
- Classification of dry and wet macular degeneration based on the ConvNeXT model.Frontiers in computational neuroscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry age-related macular degeneration (AMD) is a progressive blinding disease that currently affects millions of people worldwide with no successful treatment available. Significant research efforts are currently underway to develop therapies aimed at slowing the progression of this disease or, more notably, reversing it. Here the therapies which have reached clinical trial for treatment of dry AMD were reviewed. A thorough search of PubMed, Embase, and Clinicaltrials.gov has led to a comprehensive collection of the most recent strategies being evaluated. This review also endeavors to assess the status and future directions of therapeutics for this debilitating condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.